This study is testing a new combination of treatments for a type of colon cancer called RAS-mutant, microsatellite stable, metastatic colorectal cancer (mCRC). The treatment mix includes an anti-PD-1 antibody (a type of protein that helps the immune system fight cancer), bevacizumab (a drug that stops blood vessels from growing to the tumor), and chemotherapy. This is the first time these drugs will be used together as the initial treatment for this cancer type. Only people who have not had any treatment for their metastatic cancer can join.

Key Points:

• The study will check how safe and effective the treatment is.
• Participants must not have other untreated cancers or certain health conditions.
• Women of childbearing age must use birth control during the study.